2024 Biosimilars Pharmaceutical Companies 
STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…
European Pharmaceutical Review
FEBRUARY 26, 2024
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. CHMP meeting highlights: January 2024 The post CHMP meeting highlights: February 2024 appeared first on European Pharmaceutical Review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JULY 15, 2024
This would encourage pharmaceutical companies to enhance their R&D efforts, bolstering India’s status as a global leader in innovative healthcare solutions. ” Dr Harshit Jain, Founder & Global CEO, Doceree: “Budget 2024 is a defining moment for the pharmaceutical sector in India.
Express Pharma
JULY 21, 2024
Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030. This may fuel innovation, particularly for diseases prevalent in India.
Pharmaceutical Technology
MAY 23, 2023
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. This blog explores the key areas of concern for pharmaceutical companies and some of the potential implications of these reforms.
Express Pharma
OCTOBER 16, 2024
Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally.
Pharmaceutical Technology
JANUARY 10, 2023
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
Expert insights. Personalized for you.
363 
Let's personalize your content